CRC Research Update — September 16, 2026
Today's colorectal cancer research highlights
ras
A collection of 50 issues
Phase II trial examines quality of life with panitumumab-based intensified regimen
Skip to content
The CRC Digest
Phase II trial examines quality of life with panitumumab-based intensified regimen
The VOLFI trial analyzed health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with mFOLFOXIRI plus panitumumab versus FOLFOXIRI, noting that anti-EGFR antibodies like panitumumab are associated with a
CRC Research Update — September 15, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 13, 2026
Today's colorectal cancer research highlights
Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease
A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial examined quality of life in patients with RAS wild-type metastatic colorectal cancer
CRC Research Update — September 11, 2026
Today's colorectal cancer research highlights
ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC
Skip to content
The CRC Digest
▸ TREATMENT
ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC
A Phase II trial enrolled patients with RAS/BRAF wild-type metastatic colorectal cancer who had progressed on prior cetuximab-based therapy, using circulating tumor DNA testing to select patients for rechallenge
CRC Research Update — September 07, 2026
Today's colorectal cancer research highlights
Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy
Skip to content
The CRC Digest
◇ RESEARCH
Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy
A systematic review of patients with tissue RAS wild-type tumors receiving first-line chemotherapy plus anti-EGFR therapy found inconsistent results on whether ctDNA RAS status predicts outcomes, possibly due to differences in assay
CRC Research Update — September 02, 2026
Today's colorectal cancer research highlights